Global Urinary pH Modifiers Market – Industry Trends and Forecast to 2029

Market Analysis and Size

The medications used to treat problems of the kidneys, bladder, ureters, and urethra are known as genitourinary drugs. Patients suffering from diseases and infections of the genitourinary system have long relied on chemically manufactured steroids and immunosuppressants, which can cause major side effects such as sleeplessness, acne, nausea, vomiting, and diarrhoea. As a result, patients are increasingly turning to biological medications, which have fewer or no adverse effects and are more successful in treating genitourinary infections. Urine pH can induce or worsen certain illnesses, the most common of which is urolithiasis. The use of medicines that alter urine pH is frequently recommended in the treatment and prevention of such disorders.

Data Bridge Market Research analyses that the urinary pH modifiers? market was valued at USD 2.2442 billion in 2021 and is expected to reach USD 3.02 billion by 2029, registering a CAGR of 3.80% during the forecast period of 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Report Scope and Market Segmentation

Market Definition

Urinary pH modifiers are substances that raise urine's pH. They make urine more alkaline, which helps to prevent kidney stones. Making urine more alkaline aids the kidneys in the removal of toxins. The various types of urinary pH modifiers employed in the treatment of genitourinary disorders include potassium acid phosphate, sodium bicarbonate, sodium citrate, and potassium citrate.

Urinary pH Modifiers Market Dynamics

Drivers

• Increasing prevalence of renal failure

The rising prevalence of renal failure is anticipated to influence the urinary pH modifiers? market's growth. Kidney stones are a prevalent condition, with an annual incidence of eight cases per 1,000 people, according to Leonardo Ferreira of the American Academy of Family Physicians (AAFP) in March 2020. According to the same source, around 13% of men and 7% of women will develop a kidney stone over their lifetime, with a total incidence of urinary retention in the United States ranging from 4.5 to 6.8% per 1,000 males.

• Rising prevalence of diabetes

The increasing prevalence of diabetes is expected to flourish the market’s growth rate during the forecast period of 2022-2029. Patients with diabetes are particularly vulnerable to urinary tract infections. Due to the narrow length of the urethra, which allows bacteria to enter more easily, women are more susceptible to this disease. According to the International Diabetes Federation, the global prevalence of diabetes is expected to rise to 552 million by 2030, up from 366 million in 2011. The rising prevalence of diabetes is expected to increase demand for genitourinary medications in the coming years. Urinary Tract Infections (UTIs) infect more than 150 million individuals worldwide each year, costing the healthcare system about USD 6 billion in direct costs. Bladder cancer affects approximately 2.4 percent of women and men at some point in their lives.

Furthermore, rising initiatives by public and private organizations to spread awareness will expand the urinary pH modifiers? market. Additionally, rising level of governmental funding towards healthcare and surging level of disposable income will result in the expansion of urinary pH modifiers? market. Along with this, rising frequency of cancer and increasing geriatric population will enhance the growth rate of the market.

Opportunities

• Increase in the number of product launches

During the forecast timeline, the industry is expected to thrive due to an increase in the number of product launches. For instance, the FDA approved cefiderocol (FETROJA) in November 2019 for complicated urinary tract infections (cUTI), including pyelonephritis, caused by susceptible Gram-negative microorganisms such as Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Pseudomonas aeruginosa, and Entero. This will provide beneficial opportunities for the urinary pH modifiers? market growth.

• Rising number of mergers and acquisitions

The market is expected to rise in the next years as the number of mergers and acquisitions increases. For illustration, AbbVie Inc. agreed to pay USD 63 billion for competitor manufacturer, Allergan Plc in June 2019, the latest acquisition in an industry where some of the top businesses have been willing to pay a high premium to answer doubts about their future prospects. Due to the merger of these two firms, the product line comprising of pharmaceuticals for the treatment of genitourinary illnesses would gain a larger distribution channel, which will benefit market growth throughout the forecast period.

Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the urinary pH modifiers? market growth during the forecast period.

Restraints/Challenges

On the other hand, high cost associated with drug development and distribution will obstruct the market’s growth rate. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the urinary pH modifiers? market. Additionally, surging number of counterfeit drugs and lack of awareness among people about the infection as well as drugs will act as market restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This urinary pH modifiers? market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the urinary pH modifiers? market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Urinary pH modifiers? market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Urinary pH Modifiers Market

The unusual rise in coronavirus-infected patients hampered access to other primary care services and led in a large decline in diagnoses other than COVID-19, such as genitourinary tract infection. Coronaviruses can induce urological symptoms when they infect the genitourinary system, according to a research published in the Asian Journal of Urology in July 2021. COVID-19 is the cause of genitourinary organ damage and dysfunction. Several investigations have discovered that COVID-19 patients had kidney damage. Furthermore, COVID-19 infection poses the greatest harm to the respiratory, digestive, and reproductive systems, as per a study released in the International Journal of Environmental Research and Public Health in April 2020.  COVID-19 has a considerable impact on the genitourinary market. However, as a consequence of high demand for COVID-19 vaccines and treatment medications, the pharmaceutical and biotechnology industries are expected to increase significantly in the next years.

Global Urinary pH Modifiers Market Scope

The urinary pH modifiers? market is segmented on the basis of drug, indication, dosage, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Indication

• Alkalosis
• Alkylating Agent Cystitis
• Asystole
• Gastroesophageal reflux disease (GERD)
• Diabetic Ketoacidosis
• Hyperkalemia
• Hyponatremia
• Indigestion
• Metabolic Acidosis
• Nephrolithiasis
• Urinary Acidification
• Urinary Alkalinization
• Others

Drug

• Potassium Acid Phosphate
• Sodium Bicarbonate
• Sodium Citrate
• Potassium Citrate

Dosage

• Injection
• Tablets
• Solution
• Powder
• Others

Route of Administration

• Intravenous
• Extracorporeal
• Oral
• Others

 End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Urinary pH Modifiers Market Regional Analysis/Insights

The urinary pH modifiers? market is analyzed and market size insights and trends are provided by country, drug, indication, dosage, route of administration, end-users and distribution channel as referenced above.

The countries covered in the urinary pH modifiers? market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the urinary pH modifiers? market because of the increasing prevalence of major genitourinary diseases in this region. Additionally, growing presence of major key players and well-established healthcare infrastructure will further propel the market’s growth rate in this region.

Asia-Pacific is expected to grow during the forecast period of 2022-2029 due to rising level of disposable income and improvements in healthcare infrastructure in this region. Also, rapid high R&D investment deployed by the global players will further propel the market’s growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Urinary pH Modifiers Market Share Analysis

The urinary pH modifiers? market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to urinary pH modifiers? market.

Some of the major players operating in the urinary pH modifiers? market are:

• Sanofi (France)
• Novartis AG (Switzerland)
• Teva Pharmaceutical Industries Ltd. (Ireland)
• Pfizer Inc. (US)
• GlaxoSmithKline plc (UK)
• Johnson & Johnson Private Limited (US)
• Eli Lilly and Company (US)
• Abbott (US)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Mylan N.V. (US)
• Melinta Therapeutics LLC (US)
• Merck & Co., Inc. (US)
• AstraZeneca (UK)
• Ionis Pharmaceuticals (US)
• Genentech Inc. (US)
• Bristol-Myers Squibb Company (US)
• Allergan (Ireland)
• Cipla Inc. (US)
• Astellas Pharma Inc. (Japan)
• Bayer AG (Germany)

SKU-68379